

EQT to Sell Shares of Certara to Arsenal for \$449 Million

11.07.22



Simpson Thacher is representing Certara, Inc. (Nasdaq: CERT) and funds controlled by EQT Private Equity in connection with the sale by EQT of approximately 30 million shares of Certara to Arsenal Capital Partners at a price of \$15 per share. Upon closing of the transaction, which is subject to HSR regulatory approval, Arsenal will own approximately 22% of diluted shares outstanding of Certara.

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

EQT is a purpose-driven global investment organization with EUR 77 billion in assets under management as of 30 June 2022, across 36 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately EUR 29 billion and more than 280,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

The Simpson Thacher team includes: Michael T. Holick, Frederick W.P. de Albuquerque, Matthew Wheatley and Zachary Cracknell (M&A); Bill Brentani, Kelli Schultz and Jonathan Kachiu (Capital Markets); and Jonathan Goldstein (Tax).

Team and Contacts

Michael Holick

Partner

mholick@stblaw.com

+1-212-455-3733

Matthew Wheatley

Associate

matthew.wheatley@stblaw.com

+1-212-455-3341

William Brentani

Frederick De Albuquerque

Partner

fred.dealbuquerque@stblaw.com

+1-650-251-5281

Zachary Cracknell

Associate

zachary.cracknell@stblaw.com

+1-212-455-2987

Kelli Schultz-Panas

Partner
wbrentani@stblaw.com
+1-650-251-5110

Jonathan Kachiu
Associate
jonathan.kachiu@stblaw.com
+1-650-251-5014

Partner
kschultz@stblaw.com
+1-650-251-5148

Jonathan Goldstein
Partner
jgoldstein@stblaw.com
+1-212-455-2048

